The final stage of Novavax’s COVID-19 vaccine trial will take place in the UK

0
0


The American company Novavax, Inc. begins the final phase of clinical trials of a potential vaccine against coronavirus COVID-19 in the UK against the backdrop of a spike in infections, according to British media.

“In the UK, there is a high prevalence of SARS-CoV-2 (coronavirus – IF), it is expected to continue, (therefore – IF) we are optimistic that the crucial third phase of clinical trials will take place quickly and indicate the effectiveness of NVX- CoV2373 (the name of the vaccine) in the near future, “the media quoted Glenn as saying.

According to Sky News, Novavax plans to test the vaccine with 10,000 volunteers aged 18 to 84 over the next four to six weeks.

The company stressed that at least a quarter of clinical trial participants will be over 65 years old. The trials will focus on the group most susceptible to coronavirus infection, including ethnic minorities.

It is reported that half of the volunteers will receive two doses of NVX-CoV2373 together with Matrix-M adjuvant, a complex of substances that enhances the effect of the vaccine. The second half of the volunteers will be given a placebo.

According to Sky News, about 400 volunteers will be immunized with the COVID-19 vaccine and the seasonal flu vaccine to test the effectiveness of the interaction between the two vaccines.

In case of positive test results, the vaccine can be used not only in the UK but also in other countries.

“It is expected that the data from these tests can serve as a basis for regulatory material required for licensing in the UK, EU and other countries,” Glenn was quoted as saying by Sky News.

According to Novavax, before the final stage of the trials, the vaccine was “well tolerated in general” and elicited a “stable immune response” that was stronger than in recovering patients.

In August, the British government announced Novavax support in the final phase of clinical trials.

Sky News reminds that the Novavax coronavirus vaccine is the second vaccine to be tested in the UK. The first was a vaccine jointly developed by Oxford University and the Anglo-Swedish company AstraZeneca.

More than 100 possible coronavirus vaccines are being developed worldwide.

On Thursday, the UK registered the highest increase in new cases of coronavirus COVID-19 since the beginning of the pandemic – in 24 hours in the country detected 6.6 thousand new cases. The day before, this figure was 6.1 thousand.

This week, Prime Minister Boris Johnson called on the British to “show discipline and determination” to avoid a second possible national quarantine as a result of COVID-19.

At the same time, Johnson previously announced the introduction of new restrictive measures to combat coronavirus in England, including the need to transfer office workers to remote mode and close pubs, bars and restaurants after 22:00.

The total number of coronavirus cases in the UK exceeds 416 thousand, with 41.9 thousand infected.

LEAVE A REPLY

Please enter your comment!
Please enter your name here